Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy Drugs

기사 요약

FDA accepts Sarepta's filings seeking traditional approval for AMONDYS 45 and VYONDYS 53, with a decision expected by February 2027.